Uncaria tomentosa stimulates the proliferation of myeloid progenitor cells  by Farias, Iria et al.
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Ethnopharmacological  relevance:  The  Asháninkas,  indigenous  people  of  Peru,  use  cat’s  claw  (Uncaria
tomentosa)  to  restore  health.  Uncaria  tomentosa  has  antioxidant  activity  and  works  as  an  agent  to  repair
DNA  damage.  It causes  different  effects  on  cell  proliferation  depending  on  the  cell  type  involved;  specif-
ically,  it  can  stimulate  the  proliferation  of  myeloid  progenitors  and  cause  apoptosis  of  neoplastic  cells.
Neutropenia  is the  most  common  collateral  effect  of  chemotherapy.  For  patients  undergoing  cancer  treat-
ment,  the  administration  of a  drug  that  stimulates  the  proliferation  of  healthy  hematopoietic  tissue  cells
is very  desirable.
It  is  important  to  assess  the  acute  effects  of  Uncaria  tomentosa  on  granulocyte-macrophage  colony-
forming  cells  (CFU-GM)  and  in  the  recovery  of  neutrophils  after  chemotherapy-induced  neutropenia,  by
establishing  the  correlation  with  ﬁlgrastim  (rhG-CSF)  treatment  to evaluate  its  possible  use  in  clinical
oncology.
Materials  and  methods:  The  in  vivo  assay  was  performed  in ifosfamide-treated  mice  receiving  oral  doses
of 5 and  15  mg  of Uncaria  tomentosa  and  intraperitoneal  doses  of  3  and  9  g  of  ﬁlgrastim,  respectively,  for
four  days.  Colony-forming  cell  (CFC)  assays  were  performed  with  human  hematopoietic  stem/precursor
cells  (hHSPCs)  obtained  from  umbilical  cord  blood  (UCB).
Results:  Bioassays  showed  that  treatment  with  Uncaria  tomentosa  signiﬁcantly  increased  the neutrophil
count,  and  a potency  of  85.2%  was  calculated  in  relation  to ﬁlgrastim  at the corresponding  doses  tested.
An in  vitro  CFC  assay  showed  an  increase  in  CFU-GM  size  and  mixed  colonies  (CFU-GEMM)  size  at  the
ﬁnal concentrations  of  100  and  200  g extract/mL.
Conclusions:  At  the tested  doses,  Uncaria  tomentosa  had  a  positive  effect  on  myeloid  progenitor  number
and  is promising  for use  with  chemotherapy  to minimize  the  adverse  effects  of this  treatment.  These
results  support  the  belief  of  the  Asháninkas,  who  have  classiﬁed  Uncaria  tomentosa  as  a ‘powerful  plant’.
Abbreviations: BFU-E, burst forming units-erythroid; CFC assay, colony-forming
ell  assays; CFU-E, colony-forming units-erythroid; CFU-GEMM, colony-forming
nit-granulocyte/erythrocyte/macrophage/megakaryocyte; CFU-GM, colony-
orming unit-granulocyte/macrophage; CSFs, colony stimulating growth factors;
SH, glutathione; GM-CSF, granulocyte/macrophage colony-stimulating factor;
HSPCs, human hematopoietic stem/precursor cells; IL, interleukin; NPSH, non-
rotein thiols; NF-kappa B, nuclear factor kappa B; POAs, pentacyclic oxindole
lkaloids; ROS, reactive oxygen species; SOD, superoxide dismutase; TOAs, tetra-
yclic oxindole alkaloids; TNF-, tumor necrosis factor ; UCB, umbilical cord
lood; WBC, white blood cell.
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1. Introduction
Uncaria tomentosa belongs to the Rubiaceae family and is com-
monly known as cat’s claw. It is a woody vine native to the Amazon
rainforest and other tropical areas of South and Central America.
This plant has been used in traditional and cultural practices in
South America for centuries, especially in Peru. References exist
regarding indigenous groups such as the Asháninkas who use
preparations of ‘powerful plants’ to restore health, and Uncaria
Open access under the Elsevier OA license.tomentosa is one of these plants (Keplinger et al., 1999). Today,
this plant is widely used in Peruvian traditional medicine as an
anti-inﬂammatory, contraceptive, and cytostatic remedy (Aquino
et al., 1991). It has been used in patients with rheumatic diseases
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Mur  et al., 2002) or cancer (Gonzales and Valerio, Jr., 2006) due its
ntioxidant (Pilarski et al., 2006) and anti-inﬂammatory properties
Allen-Hall et al., 2007). In vitro and in vivo studies using animal
odels have also demonstrated that it has DNA repair activity
Sheng et al., 2000a).  Furthermore, micromolar concentrations of its
uriﬁed pentacyclic oxindole alkaloids (POAs) inhibit the growth of
eoplastic cells. For example, mitraphylline can induce apoptosis of
uman Ewing’s sarcoma (MHH-ES-1) cells and breast cancer cells
MT-3 cells) (García Gimenez et al., 2010), pteropodine and uncar-
ne F induce apoptosis of human lymphoblastic leukemia T cells
CCRF-CEM-C7H2) (Bacher et al., 2005), and mitraphylline induces
poptosis of human glioma (Gamgee cell) and neuroblastoma cells
SKN-BE) (Garcia Prado et al., 2007). Finally, these compounds stim-
late the proliferation of myeloid precursors (Eberlin et al., 2005).
Neutropenia is the most common collateral effect of chemother-
py and may  be a limiting factor in determining the frequency and
ose of treatment. Patients with neutropenia are predisposed to
nfection due to an absence of granulocytes; the disruption of the
ntegumentary, mucosal, and mucociliary barriers; and the inher-
nt microbial ﬂora shifts following severe illness and antimicrobial
sage (Ozer et al., 2000). Colony stimulating growth factors (CSFs),
specially for the myeloid lineage (G-CSF), are occasionally used
o minimize the effects of neutropenia. They are part of the fam-
ly of cytokines that regulate the proliferation, differentiation, and
unctional activation of myeloid hematopoietic cells. Filgrastim
recombinant human granulocyte colony-stimulating factor-rh-G-
SF) is a glycoprotein produced by recombinant DNA technology
n Escherichia coli.  Secondary administration of CSFs may  allow
hemotherapy dose maintenance, which is important because it
mproves overall survival, disease-free survival, quality of life, non-
oxicity, and cost-effectiveness (Ozer et al., 2000).
For patients undergoing cancer treatment, the administration
f a drug that stimulates the proliferation of healthy hematopoi-
tic tissue cells is desirable because it could minimize the primary
dverse effects of chemotherapy. Uncaria tomentosa has these char-
cteristics, which make it a promising auxiliary to conventional
reatments for cancer. Some studies have demonstrated the posi-
ive effect of Uncaria tomentosa on leukocyte counts over a period
f eight weeks in healthy animals (Sheng et al., 2000a)  and after
0 days of mild doxorubicin-induced neutropenia (Sheng et al.,
000b). It is important to observe its acute effect on myeloid tis-
ue using a model of severe neutropenia and to assess whether
he results obtained with the animal model can be extrapolated to
umans (Gertsch, 2009). These observations are necessary to deter-
ine possible therapeutic and toxic doses (Keplinger et al., 1999).
his study was conducted to investigate the effect of Uncaria tomen-
osa on myeloid progenitors. The objectives of this study were as
ollows: (1) to establish the dose-dependent relationship between
ncaria tomentosa and a reference drug (Filgrastim) on myeloid
ell proliferation after ifosfamide-induced neutropenia; (2) to eval-
ate the interference of Uncaria tomentosa with reactive oxygen
pecies (ROS) production using animal models; and (3) to assess
he relationship of Uncaria tomentosa with cell proliferation. The
esult was conﬁrmed using colony-forming cell (CFC) assays with
uman hematopoietic stem/precursor cells (hHSPCs).
. Materials and methods
.1. Drugs
Filgrastim (Leucin®, Bergamo, São Paulo, Brazil), ifosfamide
Glenmark, São Paulo, Brazil), and ascorbic acid (Redoxon®, Bayer,
razil) were obtained. The Uncaria tomentosa extract was pre-
ared by ultra-turrax extraction (Biotron-Kinematica AG) of ground
ark (Centroﬂora) with 70% ethanol (Dipalcool). The ﬂuid wasacology 137 (2011) 856– 863 857
centrifuged (Centrifuge Suzuki), concentrated in a heating tank
(MCA-ALW) to remove the alcohol, and spray-dried (Kohls) using
silicon dioxide (Evonik) and microcrystalline cellulose 102 (Blan-
ver) as excipients.
2.2. Analysis of dry Uncaria tomentosa extract
The following reagents were used: acetonitrile (JTBaker), tri-
ethylamine (Fluka), acetic acid (JTBaker), polyamide (Fluka),
ethanol (Vetec), and ultrapure water. Sample extraction was per-
formed using a Unique® ultrasound, model USC 5000A, 40 kHz.
Chromatographic analyses were performed on the Agilent 1100
HPLC system and a Zorbax® XDB C-18 column (150 mm × 4.6 mm,
3.5 m Agilent) at 15 ◦C. Samples (80 mg)  were diluted in 60%
ethanol (10 mL)  and subjected to sonication (20 min at 30 ◦C). Next,
2 mL  of sample were passed through a column containing 200 mg of
polyamide, and the eluate was injected into an HPLC system. Sep-
aration was  achieved using a gradient elution of water (0.2% acetic
acid) adjusted to pH 6.9 with triethylamine (A) and acetonitrile (B)
at a ﬂow rate of 0.8 mL/min. The composition of the mobile phase
was  65% of A and 35% of B in the 0–18 min  interval; a linear gradi-
ent approaching 50% of A and 50% of B in 18–29 min; 50% of A and
50% of B in 29–31 min; a linear gradient approaching 65% of A and
35% of B in 31–32 min; and 65% of A and 35% of B in 32–38 min.
Each run was followed by an equilibration period of 6 min. Detec-
tion was performed at 245 nm, and the concentration of pentacyclic
oxindole alkaloids (POA) were calculated with reference to external
calibration curves of mitraphylline (Bertol, 2010).
2.3. Laboratory animals
Male 7- to 8-week-old BALB/c mice from the Central Ani-
mal  House of the Federal University of Santa Maria (UFSM) were
housed in air-conditioned controlled conditions (room tempera-
ture 22 ± 2 ◦C and relative humidity of 65%; artiﬁcial illumination,
12 h per day) and were used when they weighed between 19 and
24 g. They were given food and water ad libitum. All animal pro-
cedures were approved by the Animal Ethics Committee of the
Universidade Federal de Santa Maria.
2.4. Biological assay
The bioassay was  performed as previously described (Dalmora
et al., 2006). The animals were allocated to Uncaria tomentosa,
ﬁlgrastim reference standard, and control groups in a fully ran-
domized method and were identiﬁed by color code for the assay.
Each group consisted of 6 mice per treatment group. Standard and
test samples were diluted to the concentrations of 6 and 18 g/mL
and 10 and 30 mg/mL, respectively, with phosphate buffered saline
containing 0.1% bovine serum albumin. A single dose of 200 mg
of ifosfamide/0.5 mL  per mouse was  injected intraperitoneally into
each animal on day 0. Multiple intraperitoneal injections of 0.5 mL
of ﬁlgrastim and oral doses of Uncaria tomentosa were given to the
ifosfamide-treated mice from day 1 to day 4. Six hours after the
last injection/administration, peripheral blood was collected from
the orbital venous sinus. Blood ﬁlms were prepared on glass slides
and stained using the May–Grünwald–Giemsa method, in which
the neutrophils were counted and expressed as a percentage of the
total number of white cells.
Another bioassay was performed as previous described, with
animals allocated into two groups: ascorbic acid and control. Ascor-
bic acid was  diluted to the concentrations of 11 mg/mL  according
Jagetia et al. (2003).  Multiple oral doses of 0.5 mL of ascorbic acid
were given to the ifosfamide-treated mice from day 1 to day 4.
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.5. Hematological analysis
The white blood cell (WBC) count was performed in a Neubauer
hamber (optical, 100×) in duplicate, and the blood ﬁlms were
tained with May–Grünwald–Giemsa for light microscopy obser-
ation. The hemoglobin concentration was determined using
rabkin’s solution at a spectrophotometric absorbance of 540 nm.
he samples were analyzed by two different individuals.
.6. Antioxidants
Non-protein thiols in the plasma were assayed and evaluated
ith the Ellman’s method (1959).  Values are expressed in mmol/mL
f protein. The determination of catalase activity in blood was car-
ied out in accordance with the modiﬁed method of Nelson and
iesow (1972).  This assay involves the changes at an absorbance
f 240 nm for 2 min  due to the catalase-dependent decomposition
f hydrogen peroxide (H2O2). The enzyme activity was  calculated
sing the molar extinction coefﬁcient (0.0432 cm−1mol−1). The
esults were expressed in picomoles/mg protein. Superoxide dis-
utase (SOD) activity measurements were based on the inhibition
f the superoxide radical reaction with adrenaline as described by
c Cord and Fridovich (1969).  In this method, SOD present in the
ample competes with the detection system for superoxide radi-
als. The units of SOD are deﬁned by the amount of enzyme that
nhibits 50% of adrenaline oxidation. The oxidation of adrenaline
eads to a colored product, adrenochrome, and is then detected
y spectrophotometry. SOD activity is determined by measuring
he speed of adrenochrome formation, observed at 480 nm,  in a
eaction medium containing glycine-NaOH (50 mM,  pH 10) and
drenaline (1 mM).
.7. Allometry calculation
To determine the mammalian metabolic rate, we used the fol-
owing formula: (MR) = aMbb, with a = 3.98, b = 0.686, and Mb = body
ass in grams (White and Seymour, 2005).
.8. Colony-forming cell (CFC) assays
CFC assays were performed with hHSPCs obtained from umbil-
cal cord blood (UCB). UCB was collected with full term deliveries
n = 2), and written informed consent was given by all mothers. All
rocedures were performed sequentially, immediately after col-
ection and in aseptic conditions. The sample was diluted 1:3 in
BS, and the mononuclear cells were separated with density gradi-
nt solution polysucrose and diatrizoate sodium (Histopaque-1077,
igma–Aldrich) following the manufacturer’s instructions. Abso-
ute and differential counting was performed (equipment Sysmex
s1000i) in the cells obtained at the interface of mononuclear
ells, and their viability was assessed by the trypan blue assay
Sigma–Aldrich). A positive selection was performed later using
mmunomagnetic separation for CD34+ progenitors on the Dynal®
D34 Progenitor Cell Selection system (InvitrogenTM Dynal®)
ccording to the manufacturer’s instructions. CD34+ cells were
btained from hemocytometer counting and assessed for viability
sing blue trypan before the CFC assays were carried out.
CFC assays were performed using semi-solid Complete
ethoCult® H4434 (methylcellulose, HSCF, HGM-CSFhIL-3, hEPO
temCells Technologies) according to the manufacturer’s instruc-
ions for human hematopoietic CFC assays (human colony-forming
ell assays using MethoCult®, Technical Manual, version 3.0, Octo-
er 2004). The Uncaria tomentosa extract was added to the culture
edium at a ﬁnal concentration of 100 and 200 g/mL before the
ddition of CD34+ cells. The medium was vortexed, and 7.5 × 102
D34+ cells were added per 1.1 mL  of medium. Then, 1.1 mL  ofacology 137 (2011) 856– 863
medium (7.5 × 102 cells) was transferred to each 35-mm plate. Cul-
tures were incubated at 37 ◦C under 5% CO2 in air and humidity
higher than 95% for 15 days. Subsequently, they were visualized
under a microscope with phase contrast. The tests were performed
in two  independent experiments and in duplicate for controls and
tests.
The trial was approved by the Human Research Ethics Commit-
tee of the Universidade Federal de Santa Catarina, Protocol number
311/2008, in November 2008.
2.9. Statistical analysis
Statistical analyses of the bioassay data were carried out accord-
ing to Finney by parallel line methods (2 ×2) using a PLA 2.0
Program (Stegmann Systemberatung, Rodgau, Germany) to calcu-
late the potency and conﬁdence intervals (P = 0.05). Analysis of
variance was performed for each assay, and the assumption of
regression and parallelism of the log dose–log response lines were
tested (P = 0.05). The data for hematological analysis were analyzed
with the EpiInfo program, version 3.5.1, from the CDC/USA. The data
were evaluated by analysis of variance and t-test and are expressed
as the mean ± SD.
3. Results
3.1. Pentacyclic oxindole alkaloids from Uncaria tomentosa
extract
The HPLC analysis of dry Uncaria tomentosa extract has a con-
tent of 2.57% POA. The concentrations of each POA were as follows:
speciophylline – 0.26%; uncarine F – 0.07%; mitraphylline – 0.80%;
isomitraphylline – 0.40%; uncarine C – 0.46%; and uncarine E –
0.58%. The chromatographic proﬁle in Fig. 1 does not include the
tetracyclic oxindole alkaloids (TOA), rhynchophylline and isorhyn-
chophylline.
3.2. Hematological evaluations
The experimental mice receiving ﬁlgrastim and Uncaria tomen-
tosa showed signiﬁcant recovery of their neutrophil counts
compared to the control group after ifosfamide-induced neutrope-
nia. Additionally, the recovery (increase) of neutrophils was four
and thirteen times higher for the two  doses of Uncaria tomen-
tosa tested, respectively. The minimum neutrophil count for the
dose of 15 mg  per mouse was 593.7 cells/L, whereas the control
group showed 0.0 cells/L, with the highest value of 211.5 cells/L.
Thus, the dose of 15 mg  of Uncaria tomentosa showed positive
qualitative effects near the normal range, while the leukocytes of
the control group were almost entirely lymphocytes (91.7%), as
shown in Table 1 and Fig. 2. Additionally, the values obtained for
the control group showed the utility of the experimental model
of ifosfamide-induced leukopenia.It is essential to establish dose
dependency with a well-established drug in clinical use in studies
with herbal remedies because they are extracts instead of puriﬁed,
active compounds. Therefore, a bioassay was  performed to com-
pare a biopharmaceutical sample of 3 and 9 g doses of ﬁlgrastim
and 5 and 15 mg  of Uncaria tomentosa.  The validity of the assay was
shown by the analysis of variance, and the results were statistically
calculated, giving a potency of 85.20%.
Ascorbic acid was used as a positive standard, in order to
evaluate antioxidant activity. The use of ascorbic acid at dose
of 5.5 mg  per mouse (250 mg/kg) resulted in leukocytes count
increase (4493.7/L, SD 1545.9, P = 0.02) when related to control
(2255.0/L, SD 724.6). But, different from the Uncaria tomentosa or
ﬁlgrastim treatment, the major increase occurred in lymphocyte
I. Farias et al. / Journal of Ethnopharmacology 137 (2011) 856– 863 859
Fig. 1. HPLC-ﬁngerprint analysis of dry extract from Uncaria tomentosa.  Speciophylline (1), uncarine F (2), mitraphylline (3), isomitraphylline (4), uncarine C (5) and uncarine
E  (6).
Table 1
Recovery of leukocytes and hemoglobin values with Uncaria tomentosa (VO) or ﬁlgrastim (IP) four days after induction of leukopenia with ifosfamide (IP) in mice.
Group Control Uncaria tomentosa Filgrastim
Dose X
n = 6
5 mg VO
n  = 6
15 mg  VO
n = 6
3 g IP
n = 6
9 g IP
n = 5
Leucocytes (cell/L) 2025.6A (1267.6) 2230.0A (1114.5) 2690.1A (1261.1) 3395.1A (2933.7) 4125A (1933.5)
Neutrophils (cell/L) 98.3C (85.4) 464.4B (255.1) 1366.5AB (605.7) 1571.9A (1408.9) 1979.5A (1672.2)
Lymphocytes (cell/L) 1919.5A (1180.0) 1608.7A (840.4) 1164.9B (544.8) 1637.7A (1440.4) 1849.8A (358.1)
Monocytes (cell/L) 27.2C (20.4) 166.8AB (180.2) 158.6B (129.8) 185.4A (136.0) 289.6A (190.3)
Hemoglobin (g/dL) 12.7A (1.9) 14.38Aa (1.8) 
Values expressed as means (SD). Values in the same row that do not share the same uppe
Fig. 2. Recovery of neutrophils (% values) with Uncaria tomentosa (VO) or ﬁlgrastim
(IP)  four days after induction of leukopenia with ifosfamide (IP) in mice. *P < 0.005 in
relation to the control group; #P < 0.05 between treatments (Ut 15 mg  × Ut 5 mg;  Fil
3  g × Ut 5 mg); data were represented as means ± SD. Ut 5 mg  = Uncaria tomentosa
d
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t
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Vry extract 10 mg/mL; dose 0.5 mL/day per animal; Ut 15 mg  = Uncaria tomentosa dry
xtract 30 mg/mL; dose 0.5 mL/day per animal; Fil 3 g = 6 g/mL, dose 0.5 mL/day
er  animal.
ount (3257.9/L, SD 88.4 vs 1873.0/L, SD 543.6 in the control
roup, P = 0.01).
.3. Oxidative stressThere were no differences in levels of non-protein thiols or in
he activities of antioxidant enzyme catalases or superoxide dismu-
ase (SOD) among Uncaria tomentosa,  ﬁlgrastin, and control groups
Table 2).
able 2
alues of antioxidants in animals treated with Uncaria tomentosa or ﬁlgrastim, after
fosfamide-induced neutropenia.
Control Uncaria tomentosa
15 mg
Filgrastim
3 g
NPSH a (mol  SH/mL) 0.73 (0.08) 0.75 (0.04) 0.73 (0.05)
SODb (UI/mg of protein) 9.09 (0.11) 7.11 (1.92) 8.41 (1.66)
Catalase (nmol/mg of protein) 9.00 (1.64) 8.81 (0,90) 7.71 (1.64)
alues expressed as mean ± SD.
a Non-protein thiols.
b Superoxide dismutase.15.55A (1.5) 13.87A (1.6) 14.95A (2.3)
r case superscript letters are signiﬁcantly different among the treatments.
The experimental mice receiving ascorbic acid showed mild
reduction (33%) on non-protein thiols levels in relation to the
control mice, four days after induction of leukopenia with ifos-
famide. There were no differences in antioxidant enzymes (data
not shown).
3.4. Allometry scale
To evaluate whether the dose tested in the animals is suitable
to be used in humans, the allometric scale was used (White and
Seymour, 2005). Allometry is the study of how a dependent variable
(metabolic rate) varies in relation to an independent variable (body
mass). The allometric comparison allows one to calculate dosages
and frequencies of drug administration to individuals based on indi-
vidual calorie needs. The Mammalian basal metabolic rate (MBR)
for this animal study (mice) was 35.2 mL  O2 h−1; for humans, it
was  7545.6 mL  O2 h−1. Thus, considering that the average weight
of animals was 24 g, mice treated with 0.5 mL  of solution contain-
ing 10 mg  of dry Uncaria tomentosa extract received 208 mg/kg of
Uncaria tomentosa that corresponded to a dose of 17.8 mg/kg or
1 g/day for a 60-kg human.
3.5. In vitro assay
CFC assays showed possible increases in cell proliferation after
Uncaria tomentosa extract administration in vitro, evidenced by the
overplating effect observed in these cultures. This effect did not
occur in the control trials conducted simultaneously with the same
cell samples. The overplating effect made it impossible to accu-
rately count the number of colonies, making it undesirable for data
collection; therefore, we opted for a semi-quantitative and quali-
tative assessment. Semi-quantitatively, the observed overplating
effect was caused by an increase in the size of granulocyte-
macrophage colony-forming cells (CFU-GM) and mixed colonies
(CFU-GEMM), presenting considerable conﬂuence/overlap (Figs.
3 and 4). Qualitatively, a reduction in the intensity of the red-
dish color given by the hemoglobin to the B-FUE colonies was
observed. This reduction was more evident at the concentration
of 200 g extract/mL, which suggests lower hemoglobinization of
these colonies in cultures with Uncaria tomentosa,  as seen in Fig.
5. Images are representative of a semi-quantitative and general
860 I. Farias et al. / Journal of Ethnopharmacology 137 (2011) 856– 863
Fig. 3. CFC assays treated with extract of Uncaria tomentosa,  ﬁnal concentration of 100 g of extract/mL medium (40×). Photo 1: CFC assay controls showing the absence of
overplating (40×). Photo 2: demonstration of the overplating effect with the addition of Uncaria tomentosa extract. Photos 3 and 4: CFU-GM and CFU-GEMM, respectively,
with  high granulocytic proliferation, occupying nearly the entire microscopic ﬁeld in extract-treated cell.
Fig. 4. CFC assays treated with dry extract of Uncaria tomentosa,  ﬁnal concentration of 200 g/mL medium. Photo 5: CFC assay control showing the absence of overplating
(40×).  Photos 6 and 7: The overplating effect is demonstrated with addition of Uncaria tomentosa extract (40×).
I. Farias et al. / Journal of Ethnopharmacology 137 (2011) 856– 863 861
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mages  of the plates of CFC assay control (Photo 8) and those treated with Uncar
xtract/mL medium, respectively, showing the reduction of the reddish color afford
ualitative evaluation of observations in control and test culture
lates.
. Discussion
The alkaloid proﬁle of the material used has great importance
n evaluating the results obtained because POAs and tetracyclic
xindole alkaloids (TOAs) have different pharmacological proper-
ies. TOAs appear to have accentuated action in the cardiovascular
nd central nervous system (Shi et al., 2003); however, POAs are
ssociated with antioxidant and anti-inﬂammatory action, as pre-
iously mentioned. Furthermore, TOAs are described to antagonize
he pharmacological functions of POAs; therefore, inducing human
ndothelial cells to release a lymphocyte-proliferation-regulation
actor (Wurm et al., 1998). Thus, the absence of TOAs in the sample
llows its use for therapeutic and research purposes in accordance
ith U.S. Pharmacopeia (USP 32, 2009).
The use of ifosfamide in the present study resulted in severe
eutropenia, as the control animals showed means of only
8 neutrophils/L. Similar events are observed in clinical oncol-
gy and are a part of the focus in this study. This situation was
eversed by Uncaria tomentosa,  in which the group receiving 15 mg
er animal showed 500 neutrophils/L or higher. The adminis-
ration/injection of Uncaria tomentosa and ﬁlgrastim during four
onsecutive days caused signiﬁcant increases in the neutrophil
ount in terms of both absolute values (cells/L) and percentage
nd promoted recovery from the severe ifosfamide-induced neu-
ropenia. Even animals that received the lower dose, corresponding
o 5 mg  of Uncaria tomentosa dry extract/day, showed a signiﬁ-
ant increase in neutrophil count compared to controls. The dose
ested was equivalent to 1 g/day of dry extract for a 60-kg human. the medium at ﬁnal concentrations of 100 and 200 g of dry extract/mL medium.
entosa extract at ﬁnal concentrations of 100 (Photo 9) and 200 (Photo 10) g of
 hemoglobin (40×).
Similar doses have been used for the treatment of rheumatic dis-
eases (Castan˜eda et al., 1998). In this study (Castan˜eda et al., 1998),
patients took 2 capsules of 150 mg  Uncaria tomentosa dry extract 3
times daily for 6 months, and their hemogram, creatinine, glucose,
transaminase, alkaline phosphatase, and urine were evaluated. Side
effects observed include epigastric pain, dizziness, bloating, con-
stipation, diarrhea, and bitterness in the mouth; however, all of
these side effects were present only transiently. These data are
consistent with those reported by National Center for Complemen-
tary and Alternative Medicine (USA) (NCCAM/NIH, 2011a),  which
has reported few side effects from cat’s claw at the recommended
dosages. Though rare, side effects may  include headaches, dizzi-
ness, and vomiting; however, ambiguity exists regarding the values
of “recommended dosages”. The low toxicity of Uncaria tomen-
tosa can be evaluated by the acute median lethal dose (LD50) to
mice of an aqueous extract with 3.5% of total POA, which was
found to be greater than 16 g/kg bodyweight (Keplinger et al.,
1999).
The two treatments (ﬁlgrastim and Uncaria tomentosa)  did not
differ in the resulting absolute number of lymphocytes compared
to controls. Sheng et al. (2000a), using an aqueous extract of
Uncaria tomentosa (C-Med100®) in healthy rats, only observed an
increase in the total number of leukocytes at doses greater than or
equal to 40 mg/kg. In a subsequent study, leukopenia induced by
the anticancer agent, doxorubicin, was  reversed with subsequent
administration of Uncaria tomentosa,  and signiﬁcant differences
compared to controls at a dose of 80 mg/kg were observed (Sheng
et al., 2000b). Using doxorubicin to induce leukopenia, the authors
achieved a slight reduction in neutropenia.
As described from the outset, Uncaria tomentosa has three prop-
erties that are related to cell proliferation, particularly in terms
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f WBCs: anti-inﬂammatory, antioxidant, and CSF-stimulating
ffects.
.1. Anti-inﬂammatory
One of the possible pathways of action of Uncaria tomentosa is
he prolongation of WBC  survival due to the inhibited activation
f NF-B (Sandoval et al., 2000; Fazio et al., 2008), which activates
everal different signals and can regulate the expression of several
ro-inﬂammatory cytokines, including TNF- (Groom et al., 2007),
nterleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), and
nterleukin-8 (IL-8). These effects subsequently decrease oxidative
tress (Pilarski et al., 2006) in the cell, which in turn reduces dam-
ge to DNA (Mammone et al., 2006). This postulated effect would
redict that WBCs survive longer in the circulation due to reduced
NA damage and enhanced DNA repair, thus elevating the number
f immune competent cells. In the 1990s, Wurm et al. demonstrated
hat the POAs from Uncaria tomentosa stimulated endothelial cells
o release a lymphocyte-proliferation-regulating factor that pro-
oted the proliferation of normal lymphocytes and inhibited the
roliferation of lymphoblasts. Akesson et al. (2003) concluded that
he increase in lymphocyte counts in animals that received Uncaria
omentosa orally for 10 weeks was likely due to increased survival in
eripheral lymphoid organs. In our study, there were no changes in
he number of lymphocytes, possibly because this study took place
uring the acute phase.
The inhibition of NF-B prolongs survival of WBCs; however, it is
eeded as a mediator for the proliferation of progenitors. Blocking
he activation of NF-B resulted in almost complete suppression
f the formation of the CFU-GM, BFU-E and CFU-E progenitors.
F-B activity is required for normal hematopoiesis and the main-
enance of hematopoietic progenitor cell function, and it acts as
 second messenger for a number of cytokines known to regulate
ematopoiesis, such as IL-3, Epo, IL-6, SCF, and GM-CSF (Bugarski
t al., 2006). Similarly, IL-6 aids granulocyte colony maintenance
nd the viability of mature neutrophils. IL-6 and G-CSF synergis-
ically increase myeloid progenitors (Suzuki et al., 1996) as G-CSF
acilitates the expansion of myeloid precursors, likely by stimulat-
ng the proliferation of monocytes to secrete IL-6 (Liu et al., 2005).
hus, one possible pathway for stimulating myeloid proliferation
y Uncaria tomentosa could be the release of IL-1 and IL-6 (Lemaire
t al., 1999). In the present study, the animals had a severe reduc-
ion in the number of neutrophils and monocytes. A decrease in the
umber of these cells impairs the production of cytokines (Groom
t al., 2007) and other stimulators of the proliferation and matura-
ion of CFU-GM. In the model of the study that we use, it is possible
hat the stimulation of the proliferation of myeloid tissue occurred
hrough another pathway.
.2. Antioxidant properties
ROS interfere with erythropoiesis because levels of reduced
lutathione are directly related to mitosis. The ifosfamide used
n in vivo tests is a DNA-alkylating agent frequently used in
hemotherapy against human malignancies. Ifosfamide and its
ajor decomposition products deplete intracellular glutathione
GSH). GSH is the major intracellular thiol reductant, protecting
ells against oxidative injury. Ifosfamide depletion of intracellular
SH in human dendritic cells (DC), T cells and natural killer (NK)
ells impairs their functional activity, which can be restored by
econstituting GSH (Kuppner et al., 2008). The assay of non-protein
hiols was not different in animals treated with Uncaria tomentosa,
ut all groups had lower values (0.73 mmol/mL  blood) than those
ound in the control rats of other studies (1.20 ± 0.10 mmol/mL  of
lasma; Spanevello et al., 2009). Also ascorbic acid, drug known toacology 137 (2011) 856– 863
have antioxidant proprieties, did not restored non-protein thiols
levels.
The use of antioxidants during cancer treatment is still contro-
versial. This duality is true because if some antioxidants scavenge
the ROS integral to the activity of certain chemotherapy drugs,
which would diminish treatment efﬁcacy, another antioxidant
might mitigate toxicity and thus allow for uninterrupted treatment
schedules and a reduced need for lowering chemotherapy doses
(NCCAM/NIH, 2011b). Moreover, the various ROS can exert differ-
ent effects according to their nature and to their intracellular level.
The same phenomena occur for antioxidants, e.g., N-acetylcysteine,
which decreases H2O2 levels, inhibits normal cell (ﬁbroblast) pro-
liferation but increases tumor cell proliferation (CT26 and Hepa 1–6
cells). In contrast, antioxidant molecules that mimic  SOD (CuDIPS
or MnTBAP) increase in vitro proliferation of normal cells but kill
tumor cells (Laurent et al., 2005).
Even in relation to oxidative stress, levels of H2O2 interfere with
the proliferation of myeloid precursors. Neutralization of H2O2
by catalase inhibits the proliferation of immature myeloid cells
and also stimulates their differentiation into mature myeloid cells.
SOD slightly decreases proliferation (Kusmartsev and Gabrilovich,
2003). Other studies have shown that Uncaria tomentosa has antiox-
idant activity, which is related to the reduction of tumor growth
(Dreifuss et al., 2010); however, contradictory results in which a
mild reduction of H2O2 (Gonc¸ alves et al., 2005) and an increased
activity of SOD have been observed (Pilarski et al., 2006). However,
in our study, no signiﬁcant differences in catalase or SOD activities
were registered between treatments.
4.3. Effect on myeloid progenitors
In the case of neutropenia due to chemotherapy, when the num-
ber of WBCs is severely diminished and the scavenging activity
of GSH is decreased, it is necessary to understand the route that
would preferentially activate recovery from neutropenia. There-
fore, to assess whether Uncaria tomentosa has a stimulating effect
on myeloid progenitors, CFC assays were conducted using hHSPCs
obtained from UCB. The addition of dry Uncaria tomentosa extract
resulted in an increase in CFU-GM size and CFU-GEMM size at the
ﬁnal concentrations of 100 and 200 g extract/mL.
It is suggested that Uncaria tomentosa extract may have positive
effects on myeloid progenitor proliferation. These data are consis-
tent with results obtained by Eberlin et al. (2005),  who documented
an increase in marrow CFU-GM and an increase in serum colony-
stimulating factor CSFs in mice treated with Uncaria tomentosa
extract (50 and 100 mg/kg).
To compare the effect on myeloid progenitors with the
antiproliferative effect of neoplastic cells described above, the
concentration of mitraphylline was  transformed from mol to
g/mL. Mitraphylline (C21H24N2O4, Molar mass 368.1736 g/mol)
was  used at 5–40 mol  (Garcia Prado et al., 2007; García Gimenez
et al., 2010), which corresponds to 1.8–14.7 g/mL. In the present
study, 100–200 g/mL of dry hydro-alcoholic extract containing
POA 2.6–5.1 g/mL was used, of which 0.8–1.6 g/mL was mit-
raphylline. Bacher et al. (2005) used larger concentrations of four
POAs (50–200 mol); therefore, the concentration needed to stim-
ulate the proliferation of myeloid precursors may be less than
the concentration needed to induce apoptosis of neoplastic cells.A
qualitative reduction in hemoglobin content was observed macro-
scopically and microscopically. Pilarski et al. (2009),  using a chicken
embryo model injected with Uncaria tomentosa extracts, detected
unfavorable changes in Mean Corpuscular Volume (MCV), Mean
Cellular Hemoglobin (MCH) and Mean Cellular Hemoglobin Con-
centration (MCHC). Further studies are necessary to evaluate if a
toxic effect occurred and to identify the possible route of action.
The leading possibility is inhibition of enzymes that participate in
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f Vitamin B12 and folic acid, as proposed by Pilarski et al. (2009).
. Conclusion
At the doses tested, Uncaria tomentosa is promising for use in
onjunction with chemotherapy because it minimizes the adverse
ffects of this treatment and attenuates neutropenia. More studies
re needed to evaluate the interaction of Uncaria tomentosa with
arious chemotherapeutic agents and cell types.
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